Genentech Inc.’s income rose 237% to $15.2...
- Share via
Genentech Inc.’s income rose 237% to $15.2 million in its first quarter, compared to $4.5 million for the year-ago period. The South San Francisco biotechnology company attributed its performance to a strong increase in the use of its growth hormone, Protropin, and its anti-blood clotting medication, Activase.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
